A 42-year-old man is admitted to the hospital with sudden-onset right-sided pleuritic ches… — USMLE Step 3

A $42$ -year-old man is admitted to the hospital with sudden-onset right-sided pleuritic chest pain and shortness of breath. He has a $2$ -month history of significant lower extremity edema and was recently diagnosed with primary membranous nephropathy. His temperature is $37.2^\circ\text{C}$ ( $99.0^\circ\text{F}$ ), blood pressure is $138/86\text{ mmHg}$ , pulse is $112/\text{min}$ , and respirations are $22/\text{min}$ . Pulse oximetry shows $91\%$ on room air. Computed tomography angiography of the chest confirms a right lower lobe segmental pulmonary embolism. The patient is administered a standard weight-based intravenous bolus of unfractionated heparin, followed by a continuous infusion. Over the next $24$ hours, the infusion rate is increased $3$ times according to a high-dose nomogram; however, the patient's activated partial thromboplastin time (aPTT) remains subtherapeutic at $32$ seconds (baseline $30$ seconds; therapeutic target $60$ - $80$ seconds). Which of the following is the most likely underlying mechanism for this patient's subtherapeutic laboratory response?

Urinary excretion of an endogenous serine protease inhibitorCevap
B
Point mutation in a procoagulant factor conferring resistance to degradation
C
Accelerated hepatic clearance via cytochrome P450 induction
D
Formation of IgG autoantibodies targeting a medication-protein complex
E
Presence of circulating immunoglobulins that bind to phospholipid-binding proteins

Cevap

The correct underlying mechanism is the urinary excretion of an endogenous serine protease inhibitor, specifically antithrombin III, which is lost due to the patient's nephrotic syndrome.

This patient with membranous nephropathy has developed a pulmonary embolism and is exhibiting heparin resistance, defined by the inability to achieve a therapeutic aPTT despite high doses of unfractionated heparin (UFH). UFH exerts its anticoagulant effect indirectly by binding to and potentiating antithrombin III (ATIII), an endogenous serine protease inhibitor that inactivates thrombin (Factor IIa) and Factor Xa. Membranous nephropathy, a cause of nephrotic syndrome, results in significant proteinuria. Because ATIII is a relatively small protein (approximately

58\text{ kDa}

), it is lost in the urine along with albumin in patients with nephrotic syndrome. The resulting acquired ATIII deficiency deprives UFH of its necessary cofactor, leading to a blunted or absent prolongation of the aPTT. In such cases, switching to a direct thrombin inhibitor or a low-molecular-weight heparin with anti-Xa level monitoring is often required.

Adım Adım Çözüm

Identify the core clinical problem from the vignette.

A patient with active nephrotic syndrome (membranous nephropathy) and a pulmonary embolism fails to reach a therapeutic aPTT despite escalating doses of unfractionated heparin, a phenomenon known as heparin resistance.

Recognizing heparin resistance is the first step in determining the pathophysiological mechanism behind the drug's failure.

Determine the molecular mechanism of action for the administered drug.

Unfractionated heparin exerts its anticoagulant effect indirectly by binding to antithrombin III (ATIII) and enhancing its ability to inactivate Factor Xa and thrombin.

Understanding how the medication works dictates which endogenous components must be present for therapeutic efficacy.

Relate the patient's underlying disease to the drug's required mechanism.

Nephrotic syndrome is characterized by heavy proteinuria, leading to the urinary loss of intermediate-weight plasma proteins. ATIII is an endogenous serine protease inhibitor with a molecular weight similar to albumin, and it is frequently lost in the urine of these patients.

Bridging the foundational science of renal protein loss with coagulation kinetics explains the acquired deficiency.

Formulate the final conclusion.

Without sufficient ATIII, unfractionated heparin cannot exert its anticoagulant effect. This acquired ATIII deficiency explains the patient's heparin resistance and failure to prolong the aPTT.

This confirms that urinary loss of a serine protease inhibitor is the exact mechanism for the subtherapeutic response.

Anahtar Kavram

Heparin resistance in patients with nephrotic syndrome occurs due to the urinary loss of antithrombin III, an endogenous serine protease inhibitor required for the anticoagulant effect of unfractionated heparin.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru